REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Overview

About this study

The purpose of this study is to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:
-Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
-No NUCALA use in the 6 months prior to enrollment.
-Participants with greater than or equal to (≥ )60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to ( ≤ ) exacerbations per year, as confirmed by the physician.
-Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
-Written informed consent.

Exclusion Criteria:
-Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare).
-Participants currently on maintenance OCS.
-Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment.
-Participants participating in an interventional study with a treatment intervention.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/29/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Thanai Pongdee, M.D.	Open for enrollment	Contact information: Kay Bachman R.N., C.C.R.C. (507) 284-5689 bachman.kay@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thanai Pongdee, M.D.

Open for enrollment

Contact information:

Kay Bachman R.N., C.C.R.C.

(507) 284-5689

bachman.kay@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials